Terminal Capping
N-terminal acetylation and C-terminal amidation modify the exposed ends of Selank. Resistance to enzymatic breakdown is the intended advantage; a reliable human Adalank half-life has not been established.
N-Acetyl Selank Amidate • Calm Focus • Stress Research
Adalank is N-acetyl Selank amidate, a terminally modified Selank analogue discussed for calmer focus and stress resilience. Its stability advantages are proposed; human evidence for the modified molecule remains limited.
Adalank is the name commonly used for N-acetyl Selank amidate, also written as NA-Selank amidate. It keeps the seven-amino-acid sequence of Selank—Thr-Lys-Pro-Arg-Pro-Gly-Pro—with an acetyl group on the N-terminus and an amide on the C-terminus. The shorthand is Ac-TKPRPGP-NH₂.
Selank is itself a synthetic analogue of tuftsin, a small immune-signaling peptide. Its research history includes anxiety-related outcomes, neurotransmission, and neurotrophic signaling. Adalank is discussed as a way to retain that general research profile while changing how quickly the peptide is broken down.
Capping a peptide’s ends can change its susceptibility to enzymes. That is a design rationale, rather than proof that Adalank has a particular half-life, crosses the blood-brain barrier better, or works more strongly than Selank in humans.
Adalank is distinct from Adamax, which belongs to the Semax family. N-acetyl Selank amidate does not contain an adamantane group.
N-terminal acetylation and C-terminal amidation modify the exposed ends of Selank. Resistance to enzymatic breakdown is the intended advantage; a reliable human Adalank half-life has not been established.
Parent Selank altered neurotransmission-related gene expression in rat frontal cortex, including GABA-related pathways. This supports a research hypothesis for Adalank, not a demonstrated receptor effect in people. Selank animal study.
Intranasal Selank has been studied for BDNF expression in the rat hippocampus. Whether N-acetyl Selank amidate reproduces the same changes remains unconfirmed. Parent-peptide BDNF research.
A small Selank trial examined anxiety symptoms alongside enkephalin activity. That work provides parent-compound context, without validating Adalank as an anxiety treatment. Selank clinical study.
These are research interests and reported goals. Evidence from Selank is identified separately from claims about Adalank itself.
A small clinical comparison studied Selank in patients with anxiety disorders. Adalank has not been shown to deliver the same clinical outcome.
Reduced distraction from stress is a common reason people discuss Adalank. Improved attention or productivity has not been demonstrated in controlled Adalank trials.
The Selank research program and anecdotal use motivate interest in stress responses. A reliable Adalank effect size or onset is not known.
Parent-peptide animal studies explore cognitive and neurotrophic pathways. These do not establish better memory in healthy people using Adalank.
Terminal modifications may change peptide stability. Claims that Adalank lasts a fixed number of hours or is several times stronger remain unverified.
The most useful scientific question is how this exact modified molecule differs from Selank in stability, exposure, activity, and tolerability.
Sign in or create a free account to view this content.
Use a nasal formulation with a suitable diluent and preservative system. This example illustrates concentration; it does not establish an Adalank formulation or a human dose.
The arithmetic example contains 10mg Adalank in 5mL final liquid volume, giving 2mg/mL. Use the documented final volume of the actual preparation.
At a measured 0.1mL per spray, 2mg/mL delivers 200mcg per spray. Check the bottle specification and actual output; another pump volume changes the amount per spray.
Keep refrigerated and protected from light according to the formulation instructions. Record the prep date in your research journal.
Wash hands, clean the work surface, and wipe vial stoppers with alcohol. Allow them to dry.
Use a new sterile syringe and needle to add 3mL BAC water down the inside vial wall when compatible with the formulation.
Swirl or roll until dissolved; do not shake.
Refrigerate after reconstitution and protect from light. Follow the formulation’s storage instructions. Record the reconstitution date in your research journal.
These are community-discussed combinations, not validated Adalank combination protocols.
Sometimes discussed when stress resilience and longer-term cognitive research goals overlap. Evidence does not establish an additive benefit.
These share the Selank backbone. Combining them makes it harder to tell which form is responsible for an effect, without a demonstrated advantage.
Adalank-specific human safety data are limited. Neither parent Selank experience nor chemical stability claims establish the safety of this modified form.
We’ve used Adalank both on its own and paired with Adamax. In our experience, it is marginally better than Selank alone, but the difference is modest. Where it stands out for us is alongside Adamax: that pairing has been our preferred way to use it.
That is our personal experience, not evidence of clinical superiority or a proven combination benefit. Our grade remains C because direct human evidence for N-acetyl Selank amidate is limited.
Peptide Protocols
Send us a message and we’ll reply to the email address you provide.